Drugs / NNC0113-2023
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03617081 | Aug → Dec 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0113-2023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03617081 ↗ |
| Route | Oral | “NNC0113-2023 orally” NCT03617081 ↗ |